EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Cellular, Acellular, and Matrix‐Like Placental Products for Diabetic Foot Ulcers: A 12‐Week Randomised‐Trial Meta‐Analysis

Zelluläre, azelluläre und matrixartige plazentare Produkte bei diabetischen Fußulzera: 12-Wochen-Metaanalyse randomisierter Studien

George Theodorakopoulos iD, David G Armstrong iD

International Wound Journal · 2026-10 · 23 (10)

DOI: 10.1111/iwj.71058 ↗

Auf einen Blick

Adjunktive plazentabürtige CAMPs erhöhten bei diabetischen Fußulzera die 12‑Wochen-Wundverschlussrate gegenüber Standardversorgung. Die Evidenz war moderat.

Fragestellung

Verbessern plazentabürtige cellular, acellular and matrix-like products (CAMPs) zusätzlich zur Standardversorgung den kompletten Wundverschluss nach 12 Wochen bei diabetischen Fußulzera?

Methode

Systematische Übersicht und Metaanalyse randomisierter bzw. quasi-randomisierter Studien; Suche in PubMed/MEDLINE, Scopus und CENTRAL bis 21. Juni 2026; Pooling mit Random-Effects-Modell, RoB 2 und GRADE.

Ergebnisse

14 randomisierte Artikel; 9 standardversorgungs-kontrollierte Vergleiche mit 944 Teilnehmenden. 298/505 (59,0 %) vs. 157/439 (35,8 %) heilten; RR 1,70 (95 %-KI 1,31–2,20), I² = 51,9 %.

Einschränkungen

Der Vorhersagebereich überquerte die Null (0,93–3,11); Heterogenität war moderat; ein einzelner Hochrisiko-Studie beeinflusste die Analyse.

Schlussfolgerung der Autor:innen

Adjunktive plazentabürtige CAMPs verbessern den 12‑Wochen-Komplettverschluss von DFUs gegenüber Standardversorgung bei moderater Sicherheit. Der durchschnittliche Nutzen ist nicht für jedes Produkt, jede Population oder jedes Setting gleich.

Kernaussagen

  • 12‑Wochen-Wundverschluss: RR 1,70 (95 %-KI 1,31–2,20)
  • 59,0 % vs. 35,8 % komplette Heilung
  • Moderate Evidenz; Vorhersageintervall 0,93–3,11

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift International Wound Journal, online erschienen am 01.10.2026. Verfasst von George Theodorakopoulos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wound and Foot Specialist, Athens, Greece. Hauptthemen laut MEDLINE: Diabetic Foot, Wound Healing, Placenta. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Placental‐derived cellular, acellular, and matrix‐like products (CAMPs) are widely used as adjuncts to standard care for diabetic foot ulcers (DFUs), but trials differ in product class, comparator, and healing window. We estimated the effect of adjunctive placental‐derived CAMPs on complete wound closure at a single, clinically meaningful 12‐week endpoint. The review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261399700) and reported per Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020, with search reporting guided by PRISMA‐S. PubMed/MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through 21 June 2026 for randomised or quasi‐randomised trials comparing a placental, amniotic, chorionic, amnion‐chorion, placental membrane, or umbilical cord‐derived product plus standard care against standard care or a non‐placental control in adults with active DFUs. The primary outcome was complete wound closure at 12 weeks. Risk ratios (RRs) were pooled in a random‐effects model (inverse‐variance, restricted maximum likelihood [REML], Hartung‐Knapp). Risk of bias was assessed with the Cochrane Risk of Bias 2 tool (RoB 2) for the 12‐week outcome and certainty with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Prespecified sensitivity analyses included odds ratios, leave‐one‐out, product‐class subgroups, and exclusion of high‐risk‐of‐bias studies. Of 474 records, 14 randomised articles were retained; 9 standard‐care‐controlled comparisons (944 participants) provided extractable 12‐week complete‐closure data for the primary analysis. Complete closure occurred in 298 of 505 product‐treated participants (59.0%) versus 157 of 439 controls (35.8%). Adjunctive CAMPs increased the likelihood of closure (RR 1.70, 95% confidence interval [CI] 1.31–2.20). Heterogeneity was moderate (I 2 = 51.9%) and the prediction interval crossed the null (0.93–3.11). The effect was robust to leave‐one‐out analysis (RR 1.59–1.81), an odds‐ratio model (odds ratio [OR] 3.36, 95% CI 1.68–6.71), and exclusion of the single high‐risk‐of‐bias trial (RR 1.73, 95% CI 1.29–2.33). Certainty was moderate, downgraded once for inconsistency. Adjunctive placental‐derived CAMPs improve 12‐week complete closure of DFUs compared with standard care, with moderate certainty. The wide prediction interval indicates that the average benefit may not be reproduced by every product, population, or setting, underscoring the need for product‐specific, standard‐care‐anchored trials and for coverage policy grounded in endpoint‐specific randomised evidence. Trial Registration: Registration number: CRD420261399700.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic FootWound HealingPlacentaHumansFemaleRandomized Controlled Trials as TopicPregnancyMaleAdultMiddle AgedAged

Stichwörter der Autor:innen

amnion‐chorion membraneamniotic membranecellular, acellular, and matrix‐like productsdiabetic foot ulcermeta‐analysisplacental‐derived productsrandomised controlled trialsstandard careumbilical cord allograftwound closure

Autor:innen und Institutionen

  • Wound and Foot Specialist, Athens, Greece.
  • BSc in Nursing, Technological Educational Institute of Patras, Patras, Greece.
  • BSc in Podiatry, Queen Margaret University, Edinburgh, UK.
  • MSc in Wound Care Treatment, University of West Attica, Aigaleo, Greece.
  • MSc in Diagnostic and Therapeutic Approach to the Diabetic Foot, University of Thessaly, Larisa, Greece.
  • MBA in Health Economics, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: George Theodorakopoulos, David G Armstrong

Zitieren

APA

Theodorakopoulos, G., & Armstrong, D. G. (2026). Cellular, Acellular, and Matrix‐Like Placental Products for Diabetic Foot Ulcers: A 12‐Week Randomised‐Trial Meta‐Analysis. International Wound Journal, 23(10). https://doi.org/10.1111/iwj.71058

Vancouver

Theodorakopoulos G, Armstrong DG. Cellular, Acellular, and Matrix‐Like Placental Products for Diabetic Foot Ulcers: A 12‐Week Randomised‐Trial Meta‐Analysis. International Wound Journal. 2026;23(10). doi:10.1111/iwj.71058

BibTeX
@article{Theodorakopoulos2026,
  author = {Theodorakopoulos, George and Armstrong, David G},
  title = {Cellular, Acellular, and Matrix‐Like Placental Products for Diabetic Foot Ulcers: A 12‐Week Randomised‐Trial Meta‐Analysis},
  journal = {International Wound Journal},
  year = {2026},
  volume = {23},
  number = {10},
  doi = {10.1111/iwj.71058}
}
Kostenlos starten →